Changes in total drug clearance with declining kidney function relates to the extent of drug clearance by the kidney. Changes in total drug clearance with.

Slides:

Advertisements

Similar presentations

Suggested approach to patients with dabigatran-associated bleeding

Advertisements

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

Several microRNAs are differentially expressed in the glomeruli between different types of kidney disease. Several microRNAs are differentially expressed.

Figure 4 Model of changes in the serum levels

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function Susan E. Shoaf, Patricia Bricmont, Suresh.

The proportion of DCD donor kidneys discarded was correlated with the proportion of NBD donor kidneys discarded within DSAs (Pearson correlation coefficient.

Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.

Conceptual model of the natural history of diabetic kidney disease.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Three-year cumulative incidence of a gout diagnosis presented by level of kidney function and sex. Three-year cumulative incidence of a gout diagnosis.

PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:

Volume 56, Pages S29-S31 (November 1999)

Conceptual model of the course of chronic kidney disease (CKD).

Representative transaxial thin computed tomography (CT) sections at mid, mid-low, and low levels of the heart from a control subject (left) showing normal.

Drug levels during the course of a dosing interval.

(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E

Seven-year cumulative incidence of ESRD according to baseline creatinine clearance (Ccr) and result of urine test for proteinuria (19). Seven-year cumulative.

Correlation between the difference in overnight pKt/V (A) or pCrCl (B) and the change in AHI following conversion from NPD to CAPD. pKt/V, peritoneal Kt/V;

Lifestyle intervention was associated with improved cardiorespiratory fitness. Lifestyle intervention was associated with improved cardiorespiratory fitness.

Mean ± SEM concentration of insulin in plasma and CSF and glucose in plasma 30 min after the intraperitoneal administration of DET or NPH insulin at different.

Calcifications in autosomal dominant polycystic kidneys.

Intrapatient variability in cyclosporine blood levels in renal transplant patients. Intrapatient variability in cyclosporine blood levels in renal transplant.

Pharmacodynamics (PD) follow pharmacokinetics (PK).

The underlying physiological basis of the HOMA model.

Ionized-to-total magnesium (Mg) and calcium (Ca) ratios are lower in patients on hemodialysis than those in patients not on dialysis. Ionized-to-total.

Drug factors associated with increased risk for nephrotoxicity.

Ratio of actual to expected rise in sodium as calculated using the Adrogué-Madias formula. Ratio of actual to expected rise in sodium as calculated using.

Mean plasma concentrations of ampicillin/sulbactam in plasma of critically ill patients with AKI undergoing extended dialysis (duration depicted by box.

Dialyzer clearance of ampicillin/sulbactam in plasma of critically ill patients with AKI undergoing extended dialysis. Dialyzer clearance of ampicillin/sulbactam.

Ca2+ infusion rates during all three protocol versions.

Unadjusted odds ratio of death at 6 mo for medications (β blockers [BBL], angiotensin-converting enzyme inhibitors [ACEI]/angiotensin receptor blockers.

Diagram of the mechanisms involved in limiting the ability of the kidney to maintain the levels of 1,25-dihydroxyvitamin D in chronic kidney disease (CKD).

The development of regional ventricular dysfunction as measured by regional wall motion abnormalities (RWMA; abnormal regions) was associated with a greater.

PTH response to the predialysis serum calcium concentration in hemodialysis patients with severe (A), moderate (B), and mild (C) hyperparathyroidism. PTH.

The results of the analysis for rates of symptomatic IDH, asymptomatic IDH, and symptoms alone remained consistent with the primary analysis. The results.

Many anticancer drugs are dosed according to body surface area (BSA), but they are dose adjusted according to measures of absolute kidney function (i.e.,

Drug clearance by metabolism can also decrease with declining kidney function. Drug clearance by metabolism can also decrease with declining kidney function.

X ⦁ X = 64 ±8 ±14 X ⦁ X ⦁ X =

Area under the curve (AUC)–targeted dosing of carboplatin using either the Cockcroft–Gault formula or the Chronic Kidney Disease Epidemiology Collaboration.

A loading dose decreases the time to achieve the target concentration.

Clinical characteristics and laboratory parameters in relation to dose of oral sodium bicarbonate. Clinical characteristics and laboratory parameters in.

The timing of gentamicin administration affects the concentration-time profile in patients using hemodialysis. The timing of gentamicin administration.

Rates of plasma sodium concentration increase before and after DDAVP administration. Rates of plasma sodium concentration increase before and after DDAVP.

Algorithm for management of drug-induced acute interstitial nephritis

Risk for chronic kidney disease (CKD) among Olmsted County, MN, stone formers and control subjects. Risk for chronic kidney disease (CKD) among Olmsted.

The same daily dose of metformin administered as different dosage regimens has differing effects on the concentration–time profile in a patient with CKD.

Comparison of Medicare reimbursement to a nephrology practice on an annual per-patient basis for care of a patient on dialysis (at two different frequencies.

Relationship between excess fluid, as determined by the difference between measured and estimated body water, and plasma albumin (R = −0.40, P = 0.011).

Among three residual kidney function (RKF) indices, only residual urine volume (UV) indicated an independent prognostic value in patients with UV≥0.1 or.

Gentamicin plasma and peritoneal dialysate concentrations in peritoneal dialysis patients with peritonitis. Gentamicin plasma and peritoneal dialysate.

Distribution of percent consistent facility aspirin use.

New dialysis starts in the United States by year in patients with and without diagnosis of diabetes. New dialysis starts in the United States by year in.

Pharmacokinetics and pharmacodynamics of diuretic action.

Bias with estimated GFR (eGFR) by age (years).

Relationship between urine flow rate and osmolality for a fixed osmolar excretion of 735 mosm/d (corresponding to an osmolar clearance of 1.7 ml/min when.

Effect of IS on proliferation, senescence, and the production of NO and ROS from endothelial cells. Effect of IS on proliferation, senescence, and the.

Annual prevalence of proteinuria, hematuria, and combined proteinuria/hematuria on first screening in junior high school children in Tokyo, Japan between.

As the patient nears the end of life (dashed arrow), there is an increasing focus on symptom control and patient goals of care and a shift in the approach.

Nuclear medicine images of a kidney transplant on postoperative day 1 with delayed graft function secondary to acute tubular necrosis. Nuclear medicine.

Dose adjustments in patients with CKD are based on the change in the concentration-time profile for the drug of interest. Dose adjustments in patients.

Plasma concentration-time profile after oral administration of a single dose. Plasma concentration-time profile after oral administration of a single dose.

Effects of vitamin K antagonists (VKA), such as warfarin, low-molecular-weight heparin (LMWH), and dabigatran, on the coagulation pathway. Effects of vitamin.

Renal hemodynamics. Renal hemodynamics. GFR (A), effective renal plasma flow (ERPF; B), and filtration fraction (FF; C) in patients with diabetes and with.

A change in either volume of distribution or clearance has differing effects on the concentration-time profile. A change in either volume of distribution.

Temporal distribution (from time 0 to 720 min after drug administration) of mean dosage-adjusted mycophenolic acid (MPA) concentrations at month 6 after.

Simplistic breakdown of the new MPGN classification using immunofluorescence as the basis and an approach to evaluation when the kidney biopsy indicated.

Increased incidence rate ratio (IRR) and 95% confidence intervals (CI) for type-specific community-acquired infections across eGFR categories within 12.

Receiver operator characteristic (ROC) curve for fasting blood glucose (FBG) predicting posttransplantation diabetes (PTD) using time 0 FBG (a) and screening.

Distribution of unilaterally discarded kidneys by discard category and KDRI (n=7625 kidneys), 2000–2015. Distribution of unilaterally discarded kidneys.

Organ quality (KDPI) of unilaterally discarded, deceased donor kidneys stratified by discard type (n=7625 kidneys), 2000–2015. Organ quality (KDPI) of.

Presentation transcript:

Changes in total drug clearance with declining kidney function relates to the extent of drug clearance by the kidney. Changes in total drug clearance with declining kidney function relates to the extent of drug clearance by the kidney. Representation on the basis of Equation 3 for drugs with three different pharmacokinetic profiles. Here, Drug A is 100% cleared by the kidney, and therefore, it is predicted that a 50% decrease in GFR will correlate with a 50% decrease in total clearance, prompting a 50% decrease in dose or doubling of the dosing interval to maintain the same mean plasma concentration. Drugs from many classes can be represented: for example, antibiotics (A: β-lactams or aminoglycosides, B: macrolides, and C: fluoroquinolones), anticoagulants (A: dabigatran, B: warfarin, and C: rivaroxaban), and β-blockers (A: atenolol, B: metoprolol, and C: bisoprolol). Unfortunately, this representation is an oversimplification, because it does not consider changes to nonrenal clearance in kidney disease that occur with some drugs as discussed in the text. Tom N. Lea-Henry et al. CJASN 2018;13:1085-1095 ©2018 by American Society of Nephrology